A study to assess the impact of adding special geriatric care during chemotherapy treatment on reducing its side effects in older patients with cancer.

An Open Label Randomized Control Study to Assess the Impact of Integrated Onco- Geriatric Care on Reducing Chemotherapy Toxicities In Older Patients With Cancer. - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/072997

Enrollment

144

Registered

2024-08-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C249- Malignant neoplasm of biliary tract, unspecified Health Condition 2: C509- Malignant neoplasm of breast of unspecified site Health Condition 3: C189- Malignant neoplasm of colon, unspecified Health Condition 4: C23- Malignant neoplasm of gallbladder Health Condition 5: C259- Malignant neoplasm of pancreas, unspecified Health Condition 6: C20- Malignant neoplasm of rectum Health Condition 7: C169- Malignant neoplasm of stomach, unspecified Health Condition 8: C349- Malig

Interventions

Intervention1: Patients receive additional onco-geriatric clinic support: Geriatric Assessment will be done by Practical Geriatric Assessment tool (recommended by ASCO) in the Onco-geriatric care. ?

Eligibility

Inclusion criteria

Inclusion criteria: Patients with histologically confirmed solid malignancies receiving first line chemotherapy for carcinoma breast (metastatic and adjuvant), metastatic carcinoma lung, metastatic GI malignancies (stomach, colon, pancreaticobiliary)

Exclusion criteria

Exclusion criteria: Patients receiving oral chemotherapy or single agent targeted therapy without chemotherapy shall be excluded.

Design outcomes

Primary

Measure	Time frame
Chemotherapy toxicitiesTimepoint: 12 weeks	—

Secondary

Measure	Time frame
Death from any causeTimepoint: Upto thirty days;Quality of life by EORTC-QLQ-ELD14Timepoint: 12 weeks	—

Countries

India

Contacts

Public ContactDr Sunu Lazar Cyriac

Amala Institute of Medical Sciences

drsunucyriac@gmail.com9567602426

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026